Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Can Anti-Metastatic Albumin-based Superoxide Dismutase Mimetic Serve as a "Moonshot" Drug for Treatment for Brain Tumors - From Medulloblastoma to Glioblastoma?

Hsia CJC, Messerli SM, Miskimins WK.

Cell Biochem Biophys. 2019 Jun;77(2):121-122. doi: 10.1007/s12013-019-00869-2. Epub 2019 May 15. No abstract available.

PMID:
31093886
2.

Use of Antimetastatic SOD3-Mimetic Albumin as a Primer in Triple Negative Breast Cancer.

Messerli SM, Schaefer AM, Zhuang Y, Soltys BJ, Keime N, Jin J, Ma L, Hsia CJC, Miskimins WK.

J Oncol. 2019 Feb 28;2019:3253696. doi: 10.1155/2019/3253696. eCollection 2019.

3.

Propranolol Promotes Glucose Dependence and Synergizes with Dichloroacetate for Anti-Cancer Activity in HNSCC.

Lucido CT, Miskimins WK, Vermeer PD.

Cancers (Basel). 2018 Nov 30;10(12). pii: E476. doi: 10.3390/cancers10120476.

4.

β2-Adrenergic receptor modulates mitochondrial metabolism and disease progression in recurrent/metastatic HPV(+) HNSCC.

Lucido CT, Callejas-Valera JL, Colbert PL, Vermeer DW, Miskimins WK, Spanos WC, Vermeer PD.

Oncogenesis. 2018 Oct 8;7(10):81. doi: 10.1038/s41389-018-0090-2.

5.

Can Macromolecular Nitroxide Work as Extracellular Superoxide Dismutase Mimetic in Cancer and Stroke Therapy?

Hsia CJC, Miskimins WK.

Cell Biochem Biophys. 2018 Dec;76(4):443-444. doi: 10.1007/s12013-018-0853-6. Epub 2018 Sep 6. No abstract available.

PMID:
30191451
6.

mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.

Coppock JD, Vermeer PD, Vermeer DW, Lee KM, Miskimins WK, Spanos WC, Lee JH.

Oncotarget. 2016 Apr 26;7(17):24228-41. doi: 10.18632/oncotarget.8286.

7.

Deregulation of Internal Ribosome Entry Site-Mediated p53 Translation in Cancer Cells with Defective p53 Response to DNA Damage.

Halaby MJ, Harris BR, Miskimins WK, Cleary MP, Yang DQ.

Mol Cell Biol. 2015 Dec;35(23):4006-17. doi: 10.1128/MCB.00365-15. Epub 2015 Sep 21.

8.

Translational Control Protein 80 Stimulates IRES-Mediated Translation of p53 mRNA in Response to DNA Damage.

Halaby MJ, Li Y, Harris BR, Jiang S, Miskimins WK, Cleary MP, Yang DQ.

Biomed Res Int. 2015;2015:708158. doi: 10.1155/2015/708158. Epub 2015 Jul 26.

9.

Mechanisms by which low glucose enhances the cytotoxicity of metformin to cancer cells both in vitro and in vivo.

Zhuang Y, Chan DK, Haugrud AB, Miskimins WK.

PLoS One. 2014 Sep 25;9(9):e108444. doi: 10.1371/journal.pone.0108444. eCollection 2014.

10.

Dichloroacetate enhances apoptotic cell death via oxidative damage and attenuates lactate production in metformin-treated breast cancer cells.

Haugrud AB, Zhuang Y, Coppock JD, Miskimins WK.

Breast Cancer Res Treat. 2014 Oct;147(3):539-50. doi: 10.1007/s10549-014-3128-y. Epub 2014 Sep 12.

11.

Synergistic anti-cancer effect of phenformin and oxamate.

Miskimins WK, Ahn HJ, Kim JY, Ryu S, Jung YS, Choi JY.

PLoS One. 2014 Jan 21;9(1):e85576. doi: 10.1371/journal.pone.0085576. eCollection 2014.

12.

Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.

Coppock JD, Wieking BG, Molinolo AA, Gutkind JS, Miskimins WK, Lee JH.

Neoplasia. 2013 Jun;15(6):620-30.

13.

Metformin and phenethyl isothiocyanate combined treatment in vitro is cytotoxic to ovarian cancer cultures.

Chan DK, Miskimins WK.

J Ovarian Res. 2012 Jul 10;5(1):19. doi: 10.1186/1757-2215-5-19.

14.

Far upstream element binding protein 1 activates translation of p27Kip1 mRNA through its internal ribosomal entry site.

Zheng Y, Miskimins WK.

Int J Biochem Cell Biol. 2011 Nov;43(11):1641-8. doi: 10.1016/j.biocel.2011.08.001. Epub 2011 Aug 9.

15.

CUG-binding protein represses translation of p27Kip1 mRNA through its internal ribosomal entry site.

Zheng Y, Miskimins WK.

RNA Biol. 2011 May-Jun;8(3):365-71. Epub 2011 May 1.

16.

Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells.

Zhuang Y, Miskimins WK.

Mol Cancer Res. 2011 May;9(5):603-15. doi: 10.1158/1541-7786.MCR-10-0343. Epub 2011 Mar 21.

17.

Phosphorylation at serine 482 affects stability of NF90 and its functional role in mitosis.

Smith NL, Miskimins WK.

Cell Prolif. 2011 Apr;44(2):147-55. doi: 10.1111/j.1365-2184.2011.00742.x.

18.
19.
20.

Cap-independent translation through the p27 5'-UTR.

Jiang H, Coleman J, Miskimins R, Srinivasan R, Miskimins WK.

Nucleic Acids Res. 2007;35(14):4767-78. Epub 2007 Jul 7.

21.

Galectin-4 is involved in p27-mediated activation of the myelin basic protein promoter.

Wei Q, Eviatar-Ribak T, Miskimins WK, Miskimins R.

J Neurochem. 2007 Jun;101(5):1214-23. Epub 2007 Apr 2.

22.
23.
24.

Regulation of p27(Kip1) by intracellular iron levels.

Wang G, Miskimins R, Miskimins WK.

Biometals. 2004 Feb;17(1):15-24.

PMID:
14977358
25.

Cyclin dependent kinase inhibitor p27(Kip1) is upregulated by hypoxia via an ARNT dependent pathway.

Wang G, Reisdorph R, Clark RE Jr, Miskimins R, Lindahl R, Miskimins WK.

J Cell Biochem. 2003 Oct 15;90(3):548-60.

PMID:
14523989
26.

Cloning and characterization of the rat myelin basic protein gene promoter.

Wei Q, Miskimins WK, Miskimins R.

Gene. 2003 Aug 14;313:161-7.

PMID:
12957387
27.
28.
29.
30.

Cyclic AMP inducibility of the myelin basic protein gene promoter requires the NF1 site.

Clark RE Jr, Miskimins WK, Miskimins R.

Int J Dev Neurosci. 2002 Apr;20(2):103-11.

PMID:
12034141
31.

p27(Kip1) enhances myelin basic protein gene promoter activity.

Miskimins R, Srinivasan R, Marin-Husstege M, Miskimins WK, Casaccia-Bonnefil P.

J Neurosci Res. 2002 Jan 1;67(1):100-5.

PMID:
11754085
32.

The major transcription initiation site of the p27Kip1 gene is conserved in human and mouse and produces a long 5'-UTR.

Coleman J, Hawkinson M, Miskimins R, Miskimins WK.

BMC Mol Biol. 2001;2:12. Epub 2001 Oct 11.

33.

Control of cyclin-dependent kinase inhibitor p27 expression by cap-independent translation.

Miskimins WK, Wang G, Hawkinson M, Miskimins R.

Mol Cell Biol. 2001 Aug;21(15):4960-7.

34.

A role for an AP-1-like site in the expression of the myelin basic protein gene during differentiation.

Miskimins R, Miskimins WK.

Int J Dev Neurosci. 2001 Feb;19(1):85-91.

PMID:
11226757
35.

Mimosine arrests cells in G1 by enhancing the levels of p27(Kip1).

Wang G, Miskimins R, Miskimins WK.

Exp Cell Res. 2000 Jan 10;254(1):64-71.

PMID:
10623466
36.

The cyclin-dependent kinase inhibitor p27Kip1 is localized to the cytosol in Swiss/3T3 cells.

Wang G, Miskimins R, Miskimins WK.

Oncogene. 1999 Sep 16;18(37):5204-10.

37.

ATF-1 is activated in response to UV irradiation in B16 melanoma cells.

Moore BA, Miskimins R, Miskimins WK.

Mol Cell Biol Res Commun. 1999 Apr;1(1):1-6.

PMID:
10329470
38.

The same xenobiotic response element is required for constitutive and inducible expression of the mammalian aldehyde dehydrogenase-3 gene.

Boesch JS, Miskimins R, Miskimins WK, Lindahl R.

Arch Biochem Biophys. 1999 Jan 15;361(2):223-30.

PMID:
9882450
39.

Involvement of MAP kinase in the cyclic AMP induction of myelin basic protein gene expression.

Clark R, Stewart M, Miskimins WK, Miskimins R.

Int J Dev Neurosci. 1998 Aug;16(5):323-31.

PMID:
9829168
40.

Cyclin-dependent kinase inhibitor p27kip1 is expressed at high levels in cells that express a myelinating phenotype.

Friessen AJ, Miskimins WK, Miskimins R.

J Neurosci Res. 1997 Nov 1;50(3):373-82.

PMID:
9364322
41.
42.

Characterization of the rat Class 3 aldehyde dehydrogenase gene promoter.

Xie YQ, Takimoto K, Pitot HC, Miskimins WK, Lindahl R.

Nucleic Acids Res. 1996 Nov 1;24(21):4185-91.

43.
45.
46.
48.

A supercoil-dependent structural alteration within the regulatory region of the human transferrin receptor gene.

Ouyang Q, Miskimins WK.

Biochem Biophys Res Commun. 1992 Feb 28;183(1):62-9.

PMID:
1543509
49.
50.

Analysis of cis-acting promoter elements using microinjected synthetic oligonucleotides.

Miskimins WK, Brown DB.

Exp Cell Res. 1990 Dec;191(2):328-31.

PMID:
2257886

Supplemental Content

Loading ...
Support Center